Correction:A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer
-
Published:2023-10
Issue:10
Volume:33
Page:1672-1672
-
ISSN:1048-891X
-
Container-title:International Journal of Gynecologic Cancer
-
language:en
-
Short-container-title:Int J Gynecol Cancer
Subject
Obstetrics and Gynecology,Oncology